Roche Looks to Combination Immunotherapies with Inovio DNA Vaccine Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 9 (Table of Contents)
Published: 18 Sep-2013
DOI: 10.3833/pdr.v2013.i9.1979 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Roche, the leading player in the oncology market, has licensed exclusive worldwide rights to two synthetic DNA vaccines from Inovio Pharmaceuticals and taken a licence to the company’s Celectra® electroporation technology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS